Showing 1-10 of about 23 articles.
EPIRUS Biopharmaceuticals, Inc.
New strategy to focus exclusively on BOW080 (eculizumab biosimilar) and BOW070 (tocilizumab biosimilar) in rare diseases with a combined target market opportunity of close to $6 billion of innovator...
EPIRUS Biopharmaceuticals, Inc.
BOSTON, March 15, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the global development and commercialization of biosimilar...
EPIRUS Biopharmaceuticals, Inc.
BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals, Inc.
UNIFORMi Study builds on prior successful Phase 1 and Phase 3 studiesIntended to support harmonized global filing for BOW015 in 2017BOW015 is a biosimilar for Remicade®, which had global sales of...
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Feb. 05, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Feb. 03, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals, Inc.
Readiness for on-time initiation of pivotal global registration study with completion of manufacturing process lockBOW015 remains on track for 2017 global filingBOW015 targets large market opportunity...
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 11, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 10, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
Showing 1-10 of about 23 articles.
